Vascular endothelial growth factor (VEGF) inhibition via injection of anti-VEGF monoclonal antibodies (e.g., bevacizumab and ranibizumab) has become the gold standard for AMD treatment in the last decade based on findings from the MARINA and ANCHOR studies [6,7]. This evidence concerns the gene VEGFA and age-related macular degeneration.